A bipartisan Senate bill dubbed the “Skinny Label, Big Savings Act” was introduced in January. The bill would expand the scope of protection afforded by section viii carve-outs, a mechanism that allows Abbreviated New Drug...more
3/4/2025
/ Abbreviated New Drug Application (ANDA) ,
Biosimilars ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
New Legislation ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry
[co-author: Kathleen Wills]
Last year, the global COVID-19 pandemic created unprecedented challenges for American courts. By making several changes, however, the U.S. Court of Appeals for the Federal Circuit was able to...more
2/3/2021
/ Abbreviated New Drug Application (ANDA) ,
Adidas ,
Administrative Law Judge (ALJ) ,
Administrative Patent Judges ,
Administrative Proceedings ,
America Invents Act ,
Appeals ,
Appointments Clause ,
Certiorari ,
Claim Construction ,
Comcast ,
Constitutional Challenges ,
Corporate Counsel ,
Covenant Not to Sue ,
Denial of Certiorari ,
Dismissals ,
Due Process ,
Estoppel ,
Evidence ,
FanDuel ,
Final Written Decisions ,
Google ,
Hewlett-Packard ,
Hulu ,
Inter Partes Reexamination ,
International Trade Commission (ITC) ,
Judicial Review ,
Lack of Authority ,
Motion to Amend ,
Nike ,
Obviousness ,
Oral Argument ,
Patent Applications ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Post-Grant Review ,
Precedential Opinion ,
Real Party in Interest ,
Section 337 ,
Subject Matter Jurisdiction ,
Thryv Inc v Click-To-Call Technologies LP ,
Time-Barred Claims ,
United States v Arthrex Inc ,
USPTO